Table 2. Multivariate COX regression model analysing risk factors for local recurrence-free survival in all patients undergoing breast conservation and radiotherapy or mastectomy followed by either adjuvant tamoxifen or a tamoxifen/anastrozole sequence during 5 years.
| RR | 25% | 75% | P | |
|---|---|---|---|---|
| Age | 1010 | 0.968 | 1054 | 0.650 |
| T | 0.887 | 0.424 | 1857 | 0.750 |
| N | 0.947 | 0.481 | 1866 | 0.875 |
| endT | 0.700 | 0.348 | 1408 | 0.317 |
| RT | 0.251 | 0.123 | 0.512 | <0.005 |
| EP | 1312 | 1164 | 1478 | <0.005 |
Abbreviations: endT=endocrine therapy; EP=EndoPredict; N=nodal status; RT=radiotherapy; T=tumour size. The genetic expression profile analysed by the EndoPredict was an independent prognostic factor for the occurrence of a local recurrence.